Relypsa Inc. (RLYP) Stock Rating Lowered by Vetr Inc.
RLYP has been the topic of a number of other reports. BTIG Research reissued a buy rating and set a $35.00 price objective on shares of Relypsa in a research report on Wednesday, June 29th. Morgan Stanley restated an underweight rating and set a $9.00 target price on shares of Relypsa in a report on Tuesday, July 12th. Cantor Fitzgerald set a $41.00 target price on shares of Relypsa and gave the company a buy rating in a report on Thursday, July 21st. Stifel Nicolaus restated a buy rating on shares of Relypsa in a report on Tuesday, June 28th. Finally, Wedbush restated a buy rating and set a $51.00 target price on shares of Relypsa in a report on Friday, June 10th. Twelve analysts have rated the stock with a hold rating and five have given a buy rating to the company. The stock currently has a consensus rating of Hold and a consensus target price of $35.87.
Shares of Relypsa (NASDAQ:RLYP) opened at 31.99 on Monday. Relypsa has a 12-month low of $10.26 and a 12-month high of $32.12. The company’s 50-day moving average is $30.31 and its 200-day moving average is $20.28.
Relypsa (NASDAQ:RLYP) last issued its quarterly earnings data on Thursday, August 4th. The company reported ($1.87) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.56) by $0.31. The business had revenue of $5.22 million for the quarter, compared to analyst estimates of $5.45 million. Equities analysts forecast that Relypsa will post ($6.33) earnings per share for the current fiscal year.
In other news, major shareholder James D. Dondero sold 37,000 shares of the stock in a transaction that occurred on Thursday, August 11th. The stock was sold at an average price of $31.96, for a total transaction of $1,182,520.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Orbimed Advisors Llc sold 4,043,600 shares of the stock in a transaction that occurred on Monday, July 25th. The shares were sold at an average price of $32.00, for a total value of $129,395,200.00. The disclosure for this sale can be found here.
Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Cornerstone Financial Partners LLC increased its position in Relypsa by 74.7% in the first quarter. Cornerstone Financial Partners LLC now owns 17,574 shares of the company’s stock worth $238,000 after buying an additional 7,512 shares in the last quarter. Cottage Street Advisors LLC increased its position in Relypsa by 0.9% in the first quarter. Cottage Street Advisors LLC now owns 18,805 shares of the company’s stock worth $255,000 after buying an additional 170 shares in the last quarter. BlackRock Group LTD increased its position in Relypsa by 49.8% in the first quarter. BlackRock Group LTD now owns 9,887 shares of the company’s stock worth $134,000 after buying an additional 3,287 shares in the last quarter. BlackRock Fund Advisors increased its position in Relypsa by 11.5% in the first quarter. BlackRock Fund Advisors now owns 1,773,301 shares of the company’s stock worth $24,028,000 after buying an additional 182,193 shares in the last quarter. Finally, JPMorgan Chase & Co. increased its position in Relypsa by 1.2% in the first quarter. JPMorgan Chase & Co. now owns 378,047 shares of the company’s stock worth $5,123,000 after buying an additional 4,419 shares in the last quarter.
Relypsa, Inc is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of polymer-based drugs to treat conditions that are often overlooked and undertreated, but that can have a serious impact on patients’ lives and even be life-threatening. The Company’s first drug candidate is Veltassa (patiromer) for oral suspension, or Veltassa, for the treatment of hyperkalemia.
To view Vetr’s full report, visit Vetr’s official website.
Receive News & Ratings for Relypsa Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Relypsa Inc. and related companies with MarketBeat.com's FREE daily email newsletter.